Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials (Q38081988)

28 August 2017

0 references

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials (English)

1 reference

28 August 2017

Tianzhu Qiu

1

1 reference

28 August 2017

Li Zhou

2

1 reference

28 August 2017

Wei Zhu

3

1 reference

28 August 2017

Tongshan Wang

4

1 reference

28 August 2017

Jian Wang

5

1 reference

28 August 2017

Yongqian Shu

6

1 reference

28 August 2017

Ping Liu

7

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

9

1 reference

28 August 2017

255-269

1 reference

28 August 2017

2

1 reference

DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci

28 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylases and transcriptional therapy with their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Developing histone deacetylase inhibitors as anti-cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylase inhibitors: novel anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Cancer risk in long-term users of valproate: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Clinical and molecular responses in lung cancer patients receiving Romidepsin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Targeting the epigenome for the treatment and prevention of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylase inhibitors specifically kill nonproliferating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylase inhibitors: gathering pace

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.173

21 January 2018

Identifiers

DOI

10.2217/FON.12.173

1 reference

28 August 2017

1 reference